IRISH MEDICINES BOARD ACTS 1995 AND 2006

MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007

(S.I. No.540 of 2007)

PA1640/001/001
Case No: 2078436

The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to

Transferred from PA0141/029/001.

Freynes & Co Limited

Orchard Road, **Clondalkin**, **Dublin 22**, **Ireland**

an authorisation, subject to the provisions of the said Regulations, in respect of the product

Sodium Cromoglicate Eyedrops, 2 %w/v

The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document.

This authorisation, unless previously revoked, shall continue in force from **05/03/2010** until **11/07/2010**.

Signed on behalf of the Irish Medicines Board this

_____

A person authorised in that behalf by the said Board.

Part II

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Sodium Cromoglicate Eyedrops 2% w/v

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml solution contains 20.0 mg of sodium cromoglicate. (2% w/v)

For excipients, see 6.1.

3 PHARMACEUTICAL FORM

Eye drops, solution.

Colourless to slightly yellow, clear, aqueous eye drops solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

For the prevention and treatment of acute or chronic allergic conjunctivitis and vernal kerato-conjunctivitis.

4.2 Posology and method of administration

For ocular use.

Adults (including the elderly) and children: One drop into each eye four times daily or as instructed by the physician in the case of high pollen challenge.

4.3 Contraindications

Use in patients hypersensitive to the active ingredient.

Use in patients hypersensitive to benzalkonium chloride.

4.4 Special warnings and precautions for use

Any preparation remaining after four weeks of opening the container should be discarded.

Since this treatment is primarily protective it should be continued as directed.

Soft contact lenses should not be worn during period of use of this product.

4.5 Interaction with other medicinal products and other forms of interaction

None known so far.

4.6 Pregnancy and lactation

Although there has been no evidence of any embryotoxic effect, this product should only be used during pregnancy on the advice of a physician.

4.7 Effects on ability to drive and use machines

None known so far.

4.8 Undesirable effects

Side effects include transient blurred vision and local stinging sensation.

4.9 Overdose

Not relevant.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Cromoglicic acid is used as disodium salt (DSCG = disodium cromoglicate; sodium cromoglycate (British Pharmacopoeia)). Animal experiments and in vitro studies have shown that this substance is able, after antigen challenge, to inhibit sensitised mast cell degranulation and thus the release of inflammatory mediators. This mast-cell stabilising effect has also been observed in humans with antigen-induced and IgE-mediated bronchospasm or in cases of allergic rhinitis. Immediate allergic reactions are correlated in particular with histamine. Sodium cromoglicate blocks the calcium channel linked with the IgE-receptor; it thus inhibits the calcium influx into the mast call mediated via this receptor, and hence mast cell degranulation. Sodium cromoglicate is bound specifically to a sodium cromoglicate-binding protein which is part of the IgE-dependent calcium channel. This mode of action applies similarly to all mucous membranes (e.g. bronchi, nose, eye, intestine).

5.2 Pharmacokinetic properties

Sodium cromoglicate is very poorly absorbed from the gastro-intestinal tract. Only about 1% of a dose is absorbed in humans via the gastro-intestinal tract. Less than 7% of an intranasal dose of sodium cromoglicate is absorbed systemically. Plasma protein binding is about 63-76%. The volume of distribution is 0.13 l/kg. Sodium cromoglicate administered intravenously (slow infusion over 30 minutes) is, on the other hand, eliminated rapidly (half-life about 13.5 minutes); the substance is eliminated almost completely after one hour.

Sodium cromoglicate is sparingly fat-soluble and is therefore not able to penetrate most of the biological membranes such as the blood-brain barrier. The concentration achieved in the respective target organ following topical application is the exclusive crucial factor for therapeutic efficacy.

Metabolic degradation of sodium cromoglicate has not been demonstrated so far; the substance is excreted almost equally divided between urine and bile.

5.3 Preclinical safety data

In rats, dose related impairment of renal function and even deaths occurred following subcutaneous injection of > 30 mg/kg sodium cromoglicate over a period of 90 days.

Neither histological abnormalities in any organ nor any effect on kidney or liver function could be seen below 30 mg/kg. The biochemical parameters remained unchanged as well. In rhesus monkeys no evidence of impairment was observed after daily doses of 50 mg/kg given over a period of six months.

Teratogenicity tests were performed in mice and rabbits. Up to a high dose of 500-540 mg/kg sodium cromoglicate administered during pregnancy, no foetal malformations could be observed. Some rabbits died, however, under this high dose. All surviving animals developed renal lesions. The mating behaviour and fertility of male and female rats were not affected during 14-day use of sodium cromoglicate.

Experience gathered so far shows no evidence of any mutagenic or carcinogenic potential.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride
Disodium edetate
Polysorbate 80
Sorbitol (E420)
Sodium hydroxide
Water for injections

6.2 Incompatibilities

None known.

6.3 Shelf Life

3 years.

Discard contents 4 weeks after opening.

6.4 Special precautions for storage

Do not store above 30°C. Keep container in the outer carton.

6.5 Nature and contents of container

A polyethylene dropper bottle fitted with a polypropylene cap.
Pack sizes 5, 10 and 13.5 ml.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Freynes & Co. Limited
Orchard Road
Clondalkin
Dublin 22

8 MARKETING AUTHORISATION NUMBER

PA 1640/1/1

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 12 July 1995
Date of last renewal: 12 July 2005

10 DATE OF REVISION OF THE TEXT

March 2010